MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/apt.17230

Медицинская библиотека · Alimentary pharmacology & therapeutics · 2022

Validation of the Achalasia Patient-Reported Outcomes Questionnaire.

Pandolfino John E, Carlson Dustin A, McGarva Josie, Kahrilas Peter J, Vaezi Michael, Katzka David, Taft Tiffany H

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

BACKGROUND

Achalasia is a debilitating major motor disorder of the oesophagus. Hypervigilance and symptom-specific anxiety substantially impact dysphagia symptom reporting, and quality of life is a critical patient outcome. Earlier achalasia symptom scales did not consider these constructs in their psychometric development.

AIM: To develop a new symptom measure, the Achalasia Patient-Reported Outcomes (APRO) Questionnaire

METHODS

Four gastroenterologists with achalasia expertise generated preliminary items. Patients reviewed items via cognitive interviews. Patients undergoing high-resolution manometry completed the APRO with Oesophageal Hypervigilance and Anxiety Scale, Northwestern Oesophageal Quality of Life Scale, and three measures of reflux and dysphagia. Full APRO psychometric assessment (reliability, validity, factor structure) was done. Cluster analysis evaluated APRO + symptom-anxiety/hypervigilance patient phenotypes.

RESULTS

We included 961 patients with normal motility and 296 with achalasia. The APRO yielded three subscales: dysphagia, reflux, chest pain with two items for weight change and diet modifications. Reliability and validity were excellent. Twenty-five percent of achalasia patients may have high levels of anxiety/hypervigilance despite low symptoms, while 8% may report severe symptoms with low anxiety/hypervigilance. The APRO significantly predicted quality of life, but less cognitive-affective processes.

CONCLUSIONS

The APRO is a reliable and valid measure of achalasia symptoms that addresses the limitations of existing questionnaires. Symptom anxiety and hypervigilance moderate the relationship between APRO and quality of life; 33% of patients with achalasia exhibit concerning patterns in symptom severity, anxiety and hypervigilance that may contribute to poorer outcomes.

Для цитирования: Pandolfino John E, Carlson Dustin A, McGarva Josie, Kahrilas Peter J, Vaezi Michael, Katzka David, Taft Tiffany H. Validation of the Achalasia Patient-Reported Outcomes Questionnaire.. Alimentary pharmacology & therapeutics. 2022. DOI: 10.1111/apt.17230.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.